For almost a decade, scientists have been intrigued by the possibility that Alzheimer’s disease might be, at least in part, a disorder of brain energy failure. The brain runs on glucose, and many early features of Alzheimer’s—reduced glucose uptake, impaired blood–brain barrier transport, neuroinflammation, and synaptic dysfunction—look like a prolonged energy crisis. That’s why GLP-1 receptor agonists such as semaglutide (Ozempic) drew such intense interest: in animal models and early human studies, GLP-1 drugs improved glucose transport into the brain, protected the blood–brain barrier, reduced inflammation, and enhanced neuronal metabolism. Mechanistically, they are one of the most biologically anti-aging drug classes to be tested in Alzheimer’s.
Most smart Alz specialists agree the progression starts years before symptoms. Clinical trials test those that are 70 and symptomatic. I’m shocked. So unlike them.
Most smart Alz specialists agree the progression starts years before symptoms. Clinical trials test those that are 70 and symptomatic. I’m shocked. So unlike them.
Thank you William for the note. I agree with you but prevention trials are tough to design and fund.